These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24582495)

  • 41. Cell-specific regulatory effects of CXCR2 on cholestatic liver injury.
    Konishi T; Schuster RM; Goetzman HS; Caldwell CC; Lentsch AB
    Am J Physiol Gastrointest Liver Physiol; 2019 Dec; 317(6):G773-G783. PubMed ID: 31604030
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Molecular mechanism of γ-aminobutyric acid inhibitory on the growth of cholangiocarcinoma QBC939 cell line].
    Zhu CL; Huang Q; Liu CH; Xie F; Zhu K
    Zhonghua Wai Ke Za Zhi; 2013 Mar; 51(3):261-5. PubMed ID: 23859331
    [TBL] [Abstract][Full Text] [Related]  

  • 43. S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas.
    Tsai JH; Huang WC; Kuo KT; Yuan RH; Chen YL; Jeng YM
    Histopathology; 2012 Dec; 61(6):1106-16. PubMed ID: 22882148
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oncolytic gene therapy combined with double suicide genes for human bile duct cancer in nude mouse models.
    Kojima Y; Honda K; Hamada H; Kobayashi N
    J Surg Res; 2009 Nov; 157(1):e63-70. PubMed ID: 19345377
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma.
    Zhang Q; Wang J; Yao X; Wu S; Tian W; Gan C; Wan X; You C; Hu F; Zhang S; Zhang H; Zhao K; Shu K; Lei T
    Front Immunol; 2021; 12():637053. PubMed ID: 34108959
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Knockdown of FGFR3 inhibits the proliferation, migration and invasion of intrahepatic cholangiocarcinoma.
    Chen YH; Yang SH; Liu LX; Hu S; Wang XJ; Liao ZJ; Huan YF; He K; Zhang XW
    Dig Liver Dis; 2023 Mar; 55(3):400-406. PubMed ID: 35999136
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatocyte signaling through CXC chemokine receptor-2 is detrimental to liver recovery after ischemia/reperfusion in mice.
    Kuboki S; Shin T; Huber N; Eismann T; Galloway E; Schuster R; Blanchard J; Edwards MJ; Lentsch AB
    Hepatology; 2008 Oct; 48(4):1213-23. PubMed ID: 18688883
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overexpression of CD151 as an adverse marker for intrahepatic cholangiocarcinoma patients.
    Huang XY; Ke AW; Shi GM; Ding ZB; Devbhandari RP; Gu FM; Li QL; Dai Z; Zhou J; Fan J
    Cancer; 2010 Dec; 116(23):5440-51. PubMed ID: 20715158
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fatty acid-binding protein 5 promotes cell proliferation and invasion in human intrahepatic cholangiocarcinoma.
    Jeong CY; Hah YS; Cho BI; Lee SM; Joo YT; Jung EJ; Jeong SH; Lee YJ; Choi SK; Ha WS; Park ST; Hong SC
    Oncol Rep; 2012 Oct; 28(4):1283-92. PubMed ID: 22825302
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adrenomedullin promotes intrahepatic cholangiocellular carcinoma metastasis and invasion by inducing epithelial-mesenchymal transition.
    Zhou C; Zheng Y; Li L; Zhai W; Li R; Liang Z; Zhao L
    Oncol Rep; 2015 Aug; 34(2):610-6. PubMed ID: 26043778
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma.
    Okabe H; Beppu T; Hayashi H; Horino K; Masuda T; Komori H; Ishikawa S; Watanabe M; Takamori H; Iyama K; Baba H
    Ann Surg Oncol; 2009 Sep; 16(9):2555-64. PubMed ID: 19548033
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice.
    Bento AF; Leite DF; Claudino RF; Hara DB; Leal PC; Calixto JB
    J Leukoc Biol; 2008 Oct; 84(4):1213-21. PubMed ID: 18653784
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma.
    Maeda T; Taguchi K; Aishima S; Shimada M; Hintz D; Larusso N; Gores G; Tsuneyoshi M; Sugimachi K; Wands JR; de la Monte SM
    Cancer Detect Prev; 2004; 28(5):313-8. PubMed ID: 15542253
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of MIF/CXCL8/CXCR2 signaling in the growth of nasopharyngeal carcinoma tumor spheres.
    Lo MC; Yip TC; Ngan KC; Cheng WW; Law CK; Chan PS; Chan KC; Wong CK; Wong RN; Lo KW; Ng WT; Lee WM; Tsao SW; Kwong LW; Lung ML; Mak NK
    Cancer Lett; 2013 Jul; 335(1):81-92. PubMed ID: 23403077
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overexpression of FoxM1 predicts poor prognosis of intrahepatic cholangiocarcinoma.
    Liu L; Wu J; Guo Y; Xie W; Chen B; Zhang Y; Li S; Hua Y; Peng B; Shen S
    Aging (Albany NY); 2018 Dec; 10(12):4120-4140. PubMed ID: 30580327
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer.
    Kawamura M; Toiyama Y; Tanaka K; Saigusa S; Okugawa Y; Hiro J; Uchida K; Mohri Y; Inoue Y; Kusunoki M
    Eur J Cancer; 2012 Sep; 48(14):2244-51. PubMed ID: 22197219
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CircNFIB inhibits tumor growth and metastasis through suppressing MEK1/ERK signaling in intrahepatic cholangiocarcinoma.
    Du J; Lan T; Liao H; Feng X; Chen X; Liao W; Hou G; Xu L; Feng Q; Xie K; Liao M; Chen X; Huang J; Yuan K; Zeng Y
    Mol Cancer; 2022 Jan; 21(1):18. PubMed ID: 35039066
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Decreased expression of galectin-3 is associated with metastatic potential of liver fluke-associated cholangiocarcinoma.
    Junking M; Wongkham C; Sripa B; Sawanyawisuth K; Araki N; Wongkham S
    Eur J Cancer; 2008 Mar; 44(4):619-26. PubMed ID: 18272359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Autocrine control of MIP-2 secretion from metastatic breast cancer cells is mediated by CXCR2: a mechanism for possible resistance to CXCR2 antagonists.
    Erin N; Nizam E; Tanrıöver G; Köksoy S
    Breast Cancer Res Treat; 2015 Feb; 150(1):57-69. PubMed ID: 25682075
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rebound increases in chemokines by CXCR2 antagonist in breast cancer can be prevented by PKCδ and PKCε activators.
    Erin N; Tavşan E; Akdeniz Ö; Isca VMS; Rijo P
    Cytokine; 2021 Jun; 142():155498. PubMed ID: 33773907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.